Improving Prematurity-Related Respiratory Outcomes at Vanderbilt

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

253 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway and the glutathione pathway. The investigators hypothesize that prematurity-related limitations in the function of these important biochemical pathways contribute to respiratory disease risk over the first year of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

NCT06373289

Bronchopulmonary Dysplasia Pulmonary Hypertension

NOT_YET_RECRUITING NA

Work of Breathing During Non-invasive Ventilation in Premature Neonates

NCT02788110

Respiratory Distress Syndrome, Newborn Bronchopulmonary Dysplasia

COMPLETED NA

Prematurity-Related Ventilatory Control: Role in Respiratory Outcomes

NCT03174301

Infant, Premature

COMPLETED

High-frequency Oscillatory Ventilation (HFOV) in Preterm Infants With Severe Respiratory Distress Syndrome (RDS)

NCT01496508

Respiratory Distress Syndrome

COMPLETED PHASE2

Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2

NCT03333161

Infant,Premature

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary goal of the IMPROV/PROP study is to identify biomarkers (biochemical, physiological and genetic) and clinical variables that are associated with and thus potentially predictive of pulmonary status in preterm infants at 1 year corrected age. IMPROV will test the hypothesis that biochemical immaturity and functional genetic variation in the urea cycle-nitric oxide (UC-NO) and glutathione (GSH) pathways influence the development and severity of bronchopulmonary dysplasia (BPD), a form of chronic lung disease that affects more than 10,000 premature infants each year in the US. IMPROV will also test the hypothesis that the duration and degree of NO insufficiency and free radical excess predicts BPD severity and correlates with persistence of lung problems after NICU discharge. Our hypothesis implicates (a) an immature liver and gastrointestinal ability to make citrulline and GSH, (b) inadequacy of nutritional amino acid substrate and (c) common genetic variations in the UC-NO and the GSH pathways in the pathogenesis of BPD. These factors limit the ability of the anatomically and functionally immature lung to respond to the physiologic and environmental stress of preterm birth. As part of the PROP multi-center study, novel approaches to characterizing lung status with non-invasive respiratory measures prior to NICU discharge will be employed. A composite primary outcome of morbidity that is based on serial parental reports of respiratory symptoms, medications, hospitalizations and dependence on technology during the first year of life has been developed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Birth Bronchopulmonary Dysplasia Chronic Lung Disease of Prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants who are less than or equal to 7 days old;
* Gestational Age (GA) between 23 weeks and 0/7 days and 28 weeks and 6/7 days

Exclusion Criteria

* The infant is not considered to be viable (decision made not to provide life-saving therapies);
* Congenital heart disease (not including PDA and hemodynamically insignificant VSD or ASD);
* Structural abnormalities of the upper airway, lungs or chest wall;
* Other congenital malformations or syndromes that adversely affect life expectancy or cardio-pulmonary development;
* Family is unlikely to be available for long-term follow-up.

Maximum Eligible Age

7 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No